key: cord-0700198-ev7qujfw
authors: Skorić, Magdalena Krbot; Rogić, Dunja; Lapić, Ivana; Šegulja, Dragana; Habek, Mario
title: Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
date: 2021-11-29
journal: Mult Scler Relat Disord
DOI: 10.1016/j.msard.2021.103435
sha: 990dc963560d1c918fc5be941c5da11dca6a8ed6
doc_id: 700198
cord_uid: ev7qujfw

OBJECTIVE The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC). METHODS In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19. RESULTS pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers. CONCLUSION Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod.

Compared to relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) is characterized by older age, higher level of disability, and higher occurrence of cardiovascular comorbidities. (1) This is of particular importance in the light of COVID-19 pandemics, as real-world studies published so far identified age and cardiovascular comorbidities as independent risk factors for poor COVID-19 outcomes, with level of neurological disability and progressive multiple sclerosis (MS) phenotypes additionally increasing this risk. (3) (4) (5) More and more data also suggest an attenuated humoral response after SARS-COV-2 infection and after COVID-19 vaccination in people with RRMS, depending on the disease modifying therapies used. (6-7) As of recently, Siponimod-a sphingosine 1-phosphate receptor modulator-has been approved for the treatment of the active SPMS. (8) As limited data exist on response to vaccination in people with SPMS (pwSPMS) treated with siponimod, the aim of this study is to determine a development of humoral response after COVID-19 vaccination in pwSPMS on siponimod, compared to healthy controls (HC).

In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19. Elecsys® Anti-SARSCoV-2 S assay (Roche Diagnostics Int, Rotkreuz, Switzerland) was used per the manufacturer's instructions, (9) using Cobas e 801 analytical unit for immunoassay tests (F. Hoffmann-La Roche Ltd.). Antibody titer 0.8 U/mL was considered positive, as recommended by the manufacturer (The WHO International Standard for COVID-19 serological tests conversion factor (BAU/mL) = 1.288; 1U/mL equals 1.288 BAU/ml (10)). All pwSPMS treated in our center, who were on treatment with siponimod for at least 6 months and who received both doses of COVID-19 vaccine, were invited to participate during their monthly visits to the clinical-administrative visits due to siponimod reimbursement. HC were aged and sex matched healthcare workers who received both doses of COVID-19 vaccine, without any neurological or immune related condition. The study was approved by the Ethical Committee of the University Hospital Center, Zagreb (02/21 AG). Statistical analysis was performed with the IBM SPSS v25 software. The data distribution was tested with the Kolmogorov-Smirnov test. The differences between qualitative variables were tested with the Chi-square test. The differences between the quantitative variables were tested with the parametric independent sample t-test and non-parametric Mann-Whitney test. P-values less than 0.05 were considered significant.

Demographic characteristics, vaccination status, and SARS-CoV2 IgG titer after vaccination are presented in Table 1 . pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p<0.001) ( Figure  1 ). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.

This study has shown blunted humoral response after COVID-19 vaccination in pwSPMS on siponimod. Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator, which binds with high affinity to both S1P receptors 1 and 5. Its effects on MS are a consequence of reduction of the lymphocyte count, which may lead to compromised immune response function and thus potentially limit the effectiveness of vaccinations. In a randomized, placebo-controlled study, siponimod treatment had no relevant effect on antibody response to Pneumococcal vaccination. However, blunted humoral response was seen after Influenza vaccination. (11) While no data on response to COVID-19 vaccination are available so far for pwSPMS on siponimod, several publications have shown blunted antibody response to COVID-19 vaccinations in fingolimod treated patients. (7, 12) In the study by Achiron and colleagues, only 1 out of 26 participants (pwMS treated with fingolimod) had an antibody response that was above the cut-off value for a positive response. (7) In another study, pwMS treated with S1P receptor modulator had lower median SARS-CoV2 IgG index, compared to pwMS receiving other or no DMT. (12) Furthermore, one study has shown that Spikevax® vaccine elicits 3.25-higher antibody response compared to Comirnaty® vaccine, suggesting that Spikevax® vaccine may be preferentially considered for patients under fingolimod. (13) Despite all these studies showing blunted humoral response in patients treated with S1P receptor modulators, one should bear in mind that the majority of pwMS on these therapies make an unremarkable recovery from COVID-19, implying that innate and T-cell responses are functional. Based on this, these patients are likely to benefit from protective or at least partially protective T-cell responses to the vaccine. (14) Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod. These results may have significant implications for management of pwSPMS in the light of the recent EMA update of 3 rd dose mRNA COVID-19 vaccines in people with weakened immune systems. (15) As a personal opinion of the authors, in all pwSPMS treated with siponimod, 3 rd dose of the Comirnaty® or Spikevax® should be recommended. Table 1 . Demographic characteristics, vaccination status and SARS-CoV2 IgG titer after vaccination. Figure 1 . SARS-CoV-2 IgG antibody titer after COVID-19 vaccination in pwSPMS on siponimod and HC.

Secondary Progressive Multiple Sclerosis: New Insights

Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study

mRNA vaccine in patients with multiple sclerosis treated with high-efficacy diseasemodifying therapies

The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays

Impact of siponimod on vaccination response in a randomized, placebo-controlled study

Impact of diseasemodifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection

CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

COVID-19 vaccines and multiple sclerosis disease-modifying therapies